Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 31;14(8):4479-4481.
doi: 10.21037/tcr-2025-879. Epub 2025 Aug 16.

Balancing evidence and individualization in adjuvant CDK4/6 therapy

Humaid O Al-Shamsi  1   2   3 , Muharrem Oner  4   5 , Kefah Mokbel  4
Affiliations
Editorial

Balancing evidence and individualization in adjuvant CDK4/6 therapy

Humaid O Al-Shamsi et al. Transl Cancer Res. .
No abstract available

Keywords: Breast; cancer; cyclin-dependent kinase 4 and 6 therapy (CDK4/6 therapy).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-879/coif). K.M. is a fractional shareholder of Datar Genetics’ stock. K.M. has received honoraria for offering academic and clinical advice to Merit Medical and QMedical corporations. Furthermore, he owns shares in HCA Healthcare UK. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Tannock IF, Khan QJ, Fojo T. Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor. J Clin Oncol 2025;43:2456-60. 10.1200/JCO-24-02683 - DOI - PubMed
    1. Freedman RA, Caswell-Jin JL, Hassett M, et al. Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2024;42:2233-5. 10.1200/JCO.24.00886 - DOI - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer. Version 1.2025.
    1. Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2024;35:159-82. 10.1016/j.annonc.2023.11.016 - DOI - PubMed
    1. Saad ED, Squifflet P, Burzykowski T, et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol 2019;20:361-70. 10.1016/S1470-2045(18)30750-2 - DOI - PMC - PubMed

LinkOut - more resources